MiMedx Group, Inc. reported a first‑quarter 2026 net loss of $0.05 per share and $59 million in net sales, a 33% decline from the $88.2 million earned in the same period a year earlier. The loss reflects a sharp contraction in the company’s core wound‑care business and a modest rebound in its surgical segment.
Wound‑care sales fell 60% to $23 million, while surgical sales grew 13% to $36 million. The wound‑care decline is attributed to the new Medicare reimbursement rules that took effect on January 1 2026, which created confusion across the industry and reduced reimbursement rates for skin‑substitute products. The surgical business, by contrast, benefited from a 13% year‑over‑year increase driven by continued demand for its implantable devices.
CEO Joseph Capper said, “The first quarter of 2026 was adversely impacted as new Medicare reimbursement policies in the advanced wound care space went into effect at the start of the year and led to significant confusion across the industry in nearly every care setting.” CFO Doug Rice added, “First quarter surgical sales of $36 million grew 13% versus the prior year period, while wound sales of $23 million declined 60%.”
Management revised its full‑year 2026 sales guidance to $260 million–$290 million, down from the previously forecasted $340 million–$360 million. The company also announced a $40 million annualized cost‑saving plan aimed at restoring profitability over the remainder of the year. The guidance cut signals management’s concern that the wound‑care market will recover more slowly than expected under the new Medicare framework.
The results missed analyst expectations: the adjusted EPS of $‑0.05 fell short of the consensus estimate of $‑0.03, and revenue of $59 million was below the $67.5 million estimate. The miss reflects the combined impact of the Medicare rule‑induced wound‑care decline and the company’s ongoing cost‑control efforts, which have not yet offset the revenue shortfall. Despite the loss, MiMedx’s cash position remains strong, and the company’s surgical segment continues to grow, offering a potential tailwind as the wound‑care market stabilizes.
The company’s guidance and cost‑saving plan underscore a cautious outlook. While the wound‑care segment faces significant regulatory headwinds, the surgical business’s double‑digit growth and the company’s ability to cut costs position MiMedx to navigate the current downturn and pursue profitability as the Medicare reimbursement environment normalizes.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.